Key Therap Company Profile

✉ Email this page to a colleague

KEY THERAP has four approved drugs.

There is one US patent protecting KEY THERAP drugs.

There are one hundred and fifty-five patent family members on KEY THERAP drugs in thirty-seven countries and twenty-two supplementary protection certificates in sixteen countries.

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Key Therap	TREZIX	acetaminophen; caffeine; dihydrocodeine bitartrate	CAPSULE;ORAL	204785-001	Nov 26, 2014		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Key Therap	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE	acetaminophen; butalbital; caffeine	CAPSULE;ORAL	206615-001	Aug 4, 2017		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Key Therap	DEXAMETHASONE	dexamethasone	TABLET;ORAL	088237-001	Apr 28, 1983		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Key Therap	ZONTIVITY	vorapaxar sulfate	TABLET;ORAL	204886-001	May 8, 2014		DISCN	Yes	No	7,304,078	⤷ Start Trial	Y	Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Key Therap	ZONTIVITY	vorapaxar sulfate	TABLET;ORAL	204886-001	May 8, 2014	7,235,567	⤷ Start Trial
Key Therap	ZONTIVITY	vorapaxar sulfate	TABLET;ORAL	204886-001	May 8, 2014	7,713,999	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1495018	CA 2015 00037	Denmark	⤷ Start Trial	PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING VORAPAXARSULPHATE; REG. NO/DATE: EU/1/14/976/001-06 20150119
1495018	PA2015027,C1495018	Lithuania	⤷ Start Trial	PRODUCT NAME: VORAPAKSARAS; REGISTRATION NO/DATE: EU/1/14/976/001 - EU/1/14/976/006 20150119
1495018	122015000053	Germany	⤷ Start Trial	PRODUCT NAME: VORAPAXAR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/14/976/001-006 20150119
1495018	1590037-6	Sweden	⤷ Start Trial	PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; REG. NO/DATE: EU/1/14/976/001 20150121
1495018	2015C/037	Belgium	⤷ Start Trial	PRODUCT NAME: VORAPAXAR, OU SON SEL OU SOLVAT PHARMACOLOGIQUEMENT ADMISSIBLE; AUTHORISATION NUMBER AND DATE: EU/1/14/976/001
1429780	SPC/GB12/058	United Kingdom	⤷ Start Trial	PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
1581193	SPC/GB12/047	United Kingdom	⤷ Start Trial	PRODUCT NAME: DEXAMETHASONE; REGISTERED: UK EU/1/10/638/001 20100727
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.